Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 194,477 shares, a decline of 81.2% from the September 15th total of 1,032,783 shares. Based on an average daily volume of 1,505 shares, the days-to-cover ratio is presently 129.2 days.
Innovent Biologics Stock Performance
Innovent Biologics stock opened at $12.14 on Friday. Innovent Biologics has a 12 month low of $9.10 and a 12 month high of $15.01. The stock’s 50 day simple moving average is $12.57 and its two-hundred day simple moving average is $11.37.
About Innovent Biologics
Innovent Biologics, Inc is a China-based biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines and biosimilars. The company’s research and development activities primarily address oncology, autoimmune diseases, metabolic disorders and other serious medical conditions.
Innovent’s portfolio includes therapies such as TYVYT (sintilimab), an immunotherapy used in certain cancer treatments, and olverembatinib, a targeted therapy for specific forms of chronic myeloid leukemia.
See Also
- Five stocks we like better than Innovent Biologics
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
